INSIGHTS INTO THE WORLD OF SEEING

Nerve Regenerative Agents for the Treatment of Eye Disorders

Landing_sect1.png
 
Landing_sect3fnl_notext.png

Preclinical up through Phase 2 dry-eye disease clinical trials have shown that NRO-1 enhanced neurite elongation of Retinal Ganglion Cells (RGCs) significantly.   

NRO-1 PROGRAMS

PRECLINICAL

PHASE 1

PHASE 2

DRY EYE DISEASE
POST LASIK SURGERY
GLAUCOMA

Leber’s Hereditary Optic Neuropathy (LHON)

Leber’s Hereditary Optic Neuropathy (LHON)

MORE PROGRAM DETAILS
 
 

BACK TO TOP